PGx testing provides insight into how patients may respond to certain medications based on DNA variants that affect pharmacokinetics and pharmacodynamics.
PGx testing equips physicians with a tool to enhance effective treatment decisions, potentially minimize the risk of adverse drug reactions, maximize efficacy, and reduce “trial and error” dosing and drug selection.
Our SmartMeds+ Pharmacogenomics test is fully aligned with FDA, CPIC, PharmGKB, AMP, and ACMG giving physicians insight into clinically actionable interactions including Phenoconversion.
We offer a comprehensive PGx panel with over 67 genes and 664 variants covering 294 medications across 22 therapeutic areas:
